Q3 2023

Filed Nov 8, 2023 · 10-Q · 39 days after period end · 0001062822-23-000058

Q3 2023 · 10-Q

Revenue

$148.00K

— vs Q3 2022

Net Income

-$50.53M

N/M vs Q3 2022

EPS Diluted

-$0.21

N/M vs Q3 2022

Operating Income-$49,631,000N/M

Operating Cash Flow

Same quarter

Metric	Q3 2023	Q3 2022	Q3 2021	Q3 2020
Revenue	$148.00K	$0.00	$0.00	$0.00
Net Income	-$50.53M	-$23.39M	-$23.12M	$82.60M
EPS Diluted	-$0.21	-$0.13	-$0.16	$0.71

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Lexicon Pharmaceuticals, Inc. · CIK 1062822 · Engraved from SEC EDGAR